

Jinsil Seong

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8040242/publications.pdf>

Version: 2024-02-01

183
papers

4,658
citations

101543

36
h-index

138484

58
g-index

186
all docs

186
docs citations

186
times ranked

4374
citing authors

#	ARTICLE	IF	CITATIONS
1	Pattern and clinical significance of lymph node metastasis from hepatocellular carcinoma.. Journal of Clinical Oncology, 2022, 40, 431-431.	1.6	0
2	Early experience of combining immune checkpoint inhibitor and radiotherapy in heavily pretreated hepatobiliary cancer.. Journal of Clinical Oncology, 2022, 40, 457-457.	1.6	0
3	Liver-directed concurrent chemoradiotherapy versus sorafenib in hepatocellular carcinoma with portal vein tumor thrombus.. Journal of Clinical Oncology, 2022, 40, 424-424.	1.6	1
4	The role of postoperative radiotherapy in hepatocellular carcinoma. Hepatobiliary Surgery and Nutrition, 2022, 11, 123-125.	1.5	1
5	Stereotactic ablative radiotherapy for pulmonary oligometastases from primary hepatocellular carcinoma: a multicenter and retrospective analysis (KROG 17-08). Japanese Journal of Clinical Oncology, 2022, 52, 616-622.	1.3	9
6	Role of adjuvant chemoradiotherapy and chemotherapy in patients with resected gallbladder carcinoma: a multi-institutional analysis (KROG 19-04). Cancer Biology and Medicine, 2022, 19, 1-14.	3.0	2
7	Implementing combined approach with radiotherapy in surgical strategy for advanced HCC. Annals of Hepato-biliary-pancreatic Surgery, 2022, 26, S14-S14.	0.1	0
8	Benefit of adjuvant radiotherapy for gallbladder cancer: a comparability-based meta-analysis. Hepatology International, 2022, , 1.	4.2	0
9	Liver-Directed Concurrent Chemoradiotherapy versus Sorafenib in Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis. Cancers, 2022, 14, 2396.	3.7	8
10	Skull Base Metastasis from Hepatocellular Carcinoma: Clinical Presentation and Efficacy of Radiotherapy. Journal of Hepatocellular Carcinoma, 2022, Volume 9, 357-366.	3.7	1
11	Combination therapy with anti-CTLA-4 cell immunoglobulin and mucin-6 domain containing molecule 3 and radiation improves antitumor efficacy in murine hepatocellular carcinoma. Journal of Gastroenterology and Hepatology (Australia), 2021, 36, 1357-1365.	2.8	8
12	Dose-Response Relationship in Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma: A Pooled Analysis of an Asian Liver Radiation Therapy Group Study. International Journal of Radiation Oncology Biology Physics, 2021, 109, 464-473.	0.8	24
13	Effect of Interleukin-7 on Radiation-Induced Lymphopenia and Its Antitumor Effects in a Mouse Model. International Journal of Radiation Oncology Biology Physics, 2021, 109, 1559-1569.	0.8	10
14	Therapeutic Guidelines for Patients with Liver Cancer from the Perspective of Radiation Oncologists. , 2021, , 155-168.		0
15	Liver Hypertrophy Following Radiotherapy. , 2021, , 295-302.		0
16	Role of Interleukin-7 in the Development of and Recovery from Radiation-Induced Lymphopenia: A Post-hoc Analysis of a Prospective Cohort. Cancer Research and Treatment, 2021, 53, 962-972.	3.0	4
17	Lymphopenia Following Radiotherapy for Hepatocellular Carcinoma. , 2021, , 317-324.		0
18	Efficacy of Local Therapy for Oligometastatic Hepatocellular Carcinoma: A Propensity Score Matched Analysis. Journal of Hepatocellular Carcinoma, 2021, Volume 8, 35-44.	3.7	16

#	ARTICLE	IF	CITATIONS
19	Improved oncologic outcomes by ablative radiotherapy in patients with bone metastasis from hepatocellular carcinoma. <i>Journal of Cancer Research and Clinical Oncology</i> , 2021, 147, 2693-2700.	2.5	17
20	Radiotherapy as an immune checkpoint blockade combination strategy for hepatocellular carcinoma. <i>World Journal of Gastroenterology</i> , 2021, 27, 919-927.	3.3	14
21	Treatment efficacy by hepatic arterial infusion chemotherapy vs. sorafenib after liver-directed concurrent chemoradiotherapy for advanced hepatocellular carcinoma. <i>Journal of Cancer Research and Clinical Oncology</i> , 2021, 147, 3123-3133.	2.5	3
22	Efficacy of radiotherapy for gastric bleeding associated with advanced gastric cancer. <i>Radiation Oncology</i> , 2021, 16, 161.	2.7	14
23	Curative liver transplantation after lung resection for advanced hepatocellular carcinoma with lung metastasis and inferior vena cava tumor thrombosis: a case report. <i>Journal of Liver Cancer</i> , 2021, 21, 181-186.	1.1	1
24	Long-term survival after multimodal treatment involving radiotherapy for huge hepatocellular carcinoma with oligometastasis: a case report. <i>Journal of Liver Cancer</i> , 2021, 21, 163-168.	1.1	0
25	Role of adjuvant radiotherapy in extrahepatic bile duct cancer: A multicenter retrospective study (Korean Radiation Oncology Group 18-14). <i>European Journal of Cancer</i> , 2021, 157, 31-39.	2.8	5
26	Adjuvant Radiotherapy for Extrahepatic Cholangiocarcinoma: A Quality Assessment-Based Meta-Analysis. <i>Liver Cancer</i> , 2021, 10, 419-432.	7.7	4
27	Optimal Timing of Radiotherapy after Incomplete Transarterial Chemoembolization for Barcelona Clinic Liver Cancer Stage B Hepatocellular Carcinoma. <i>Yonsei Medical Journal</i> , 2021, 62, 409.	2.2	6
28	Adjuvant radiotherapy and chemotherapy offer a recurrence and survival benefit in patients with resected perihilar cholangiocarcinoma. <i>Journal of Cancer Research and Clinical Oncology</i> , 2021, 147, 2435-2445.	2.5	11
29	Dose escalation in radiotherapy for incomplete transarterial chemoembolization of hepatocellular carcinoma. <i>Strahlentherapie Und Onkologie</i> , 2020, 196, 132-141.	2.0	11
30	Prognostic factors and patterns of loco-regional failure in patients with R0 resected gallbladder cancer. <i>Hpb</i> , 2020, 22, 1168-1173.	0.3	2
31	Reply to: "Can sorafenib use influence outcome when comparing stereotactic body radiation therapy with radiofrequency ablation in patients with hepatocellular carcinoma?" <i>Journal of Hepatology</i> , 2020, 73, 468-469.	3.7	0
32	Reply to: "Stereotactic body radiation therapy vs. radiofrequency ablation for HCC: More questions than answers" <i>Journal of Hepatology</i> , 2020, 73, 973-974.	3.7	0
33	Significance of lymphocyte recovery from treatment-related lymphopenia in locally advanced pancreatic cancer. <i>Radiotherapy and Oncology</i> , 2020, 151, 82-87.	0.6	16
34	Liver-directed combined radiotherapy as a bridge to curative surgery in locally advanced hepatocellular carcinoma beyond the Milan criteria. <i>Radiotherapy and Oncology</i> , 2020, 152, 1-7.	0.6	14
35	Hepatocellular Carcinoma in the COVID-19 Era: Primetime for Stereotactic Body Radiotherapy and a Lesson for the Future?. <i>Oncologist</i> , 2020, 25, e1249-e1250.	3.7	9
36	Stereotactic body radiation therapy vs. radiofrequency ablation in Asian patients with hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2020, 73, 121-129.	3.7	116

#	ARTICLE	IF	CITATIONS
37	Effectiveness and feasibility of external beam radiotherapy for hepatocellular carcinoma with inferior vena cava and/or right atrium involvement: a multicenter trial in Korea (KROG 17-10). <i>International Journal of Radiation Biology</i> , 2020, 96, 759-766.	1.8	12
38	Efficacy and Safety of Liver-Directed Concurrent Chemoradiotherapy and Sequential Sorafenib for Advanced Hepatocellular Carcinoma: A Prospective Phase 2 Trial. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 107, 106-115.	0.8	19
39	An evaluation of hepatocellular carcinoma practice guidelines from a radiation oncology perspective. <i>Radiotherapy and Oncology</i> , 2020, 148, 73-81.	0.6	23
40	Appraisal of Long-Term Outcomes of Liver-Directed Concurrent Chemoradiotherapy for Hepatocellular Carcinoma with Major Portal Vein Invasion. <i>Journal of Hepatocellular Carcinoma</i> , 2020, Volume 7, 403-412.	3.7	6
41	Optimal timing of radiotherapy for incomplete transarterial chemoembolization in BCLC stage B hepatocellular carcinoma. <i>Journal of Clinical Oncology</i> , 2020, 38, 521-521.	1.6	0
42	Dose perturbation by metallic biliary stent in external beam radiotherapy of pancreato-biliary cancers. <i>Australasian Physical and Engineering Sciences in Medicine</i> , 2019, 42, 745-756.	1.3	5
43	Changes in real-life practice for hepatocellular carcinoma patients in the Republic of Korea over a 12-year period: A nationwide random sample study. <i>PLoS ONE</i> , 2019, 14, e0223678.	2.5	14
44	Recent clinical applications of external beam radiotherapy for hepatocellular carcinoma according to guidelines, major trials and meta-analyses. <i>Journal of Medical Imaging and Radiation Oncology</i> , 2019, 63, 812-821.	1.8	17
45	Acute severe lymphopenia by radiotherapy is associated with reduced overall survival in hepatocellular carcinoma. <i>Strahlentherapie Und Onkologie</i> , 2019, 195, 1007-1017.	2.0	27
46	Dose escalation by intensity modulated radiotherapy in liver-directed concurrent chemoradiotherapy for locally advanced BCLC stage C hepatocellular carcinoma. <i>Radiotherapy and Oncology</i> , 2019, 133, 1-8.	0.6	30
47	Clinical safety and efficacy of salvage reirradiation for upper abdominal malignancies. <i>Strahlentherapie Und Onkologie</i> , 2019, 195, 526-533.	2.0	3
48	Clinical feasibility and efficacy of stereotactic body radiotherapy for hepatocellular carcinoma: A systematic review and meta-analysis of observational studies. <i>Radiotherapy and Oncology</i> , 2019, 131, 135-144.	0.6	118
49	Irradiation-Related Lymphopenia for Bone Metastasis from Hepatocellular Carcinoma. <i>Liver Cancer</i> , 2019, 8, 468-479.	7.7	14
50	A prospective Phase II study for the efficacy of radiotherapy in combination with zoledronic acid in treating painful bone metastases from gastrointestinal cancers. <i>Journal of Radiation Research</i> , 2019, 60, 242-248.	1.6	9
51	Phase I/II trial of helical IMRT-based stereotactic body radiotherapy for hepatocellular carcinoma. <i>Digestive and Liver Disease</i> , 2019, 51, 445-451.	0.9	41
52	Retrospective analysis of stereotactic body radiation therapy efficacy over radiofrequency ablation for hepatocellular carcinoma. <i>Radiotherapy and Oncology</i> , 2019, 131, 81-87.	0.6	70
53	Radiation-Induced CXCL12 Upregulation via Histone Modification at the Promoter in the Tumor Microenvironment of Hepatocellular Carcinoma. <i>Molecules and Cells</i> , 2019, 42, 530-545.	2.6	8
54	Treatment Outcome after Fractionated Conformal Radiotherapy for Hepatocellular Carcinoma in Patients with Child-Pugh Classification B in Korea (KROG 16-05). <i>Cancer Research and Treatment</i> , 2019, 51, 1589-1599.	3.0	18

#	ARTICLE	IF	CITATIONS
55	Noninvasive Biomarker for Predicting Treatment Response to Concurrent Chemoradiotherapy in Patients with Hepatocellular Carcinoma. <i>Investigative Magnetic Resonance Imaging</i> , 2019, 23, 351.	0.4	2
56	Radiation-Induced CXCL12 Upregulation via Histone Modification at the Promoter in the Tumor Microenvironment of Hepatocellular Carcinoma. <i>Molecules and Cells</i> , 2019, 42, 502.	2.6	5
57	Clinical significance of soluble programmed cell death ligand-1 (sPD-L1) in hepatocellular carcinoma patients treated with radiotherapy. <i>Radiotherapy and Oncology</i> , 2018, 129, 130-135.	0.6	69
58	What Role Does Locally Ablative Stereotactic Body Radiotherapy Play Versus Radiofrequency Ablation in Localized Hepatocellular Carcinoma?. <i>Journal of Clinical Oncology</i> , 2018, 36, 2560-2561.	1.6	6
59	Strategic application of radiotherapy for hepatocellular carcinoma. <i>Clinical and Molecular Hepatology</i> , 2018, 24, 114-134.	8.9	47
60	A nomogram for predicting survival of patients with locally advanced pancreatic cancer treated with chemoradiotherapy. <i>Radiotherapy and Oncology</i> , 2018, 129, 340-346.	0.6	17
61	Stereotactic Body Radiotherapy: Does It Have a Role in Management of Hepatocellular Carcinoma?. <i>Yonsei Medical Journal</i> , 2018, 59, 912.	2.2	14
62	Compensatory hypertrophy of the liver after external beam radiotherapy for primary liver cancer. <i>Strahlentherapie Und Onkologie</i> , 2018, 194, 1017-1029.	2.0	4
63	Plasma Cell-Free DNA as a Predictive Marker after Radiotherapy for Hepatocellular Carcinoma. <i>Yonsei Medical Journal</i> , 2018, 59, 470.	2.2	23
64	Downstaging with Localized Concurrent Chemoradiotherapy Can Identify Optimal Surgical Candidates in Hepatocellular Carcinoma with Portal Vein Tumor Thrombus. <i>Annals of Surgical Oncology</i> , 2018, 25, 3308-3315.	1.5	42
65	Inter-alpha Inhibitor H4 as a Potential Biomarker Predicting the Treatment Outcomes in Patients with Hepatocellular Carcinoma. <i>Cancer Research and Treatment</i> , 2018, 50, 646-657.	3.0	17
66	The Neutrophil-Lymphocyte Ratio and Platelet-Lymphocyte Ratio Are Prognostic Factors in Patients with Locally Advanced Pancreatic Cancer Treated with Chemoradiotherapy. <i>Gut and Liver</i> , 2018, 12, 342-352.	2.9	43
67	Radiotherapeutic strategies for hepatocellular carcinoma with portal vein tumour thrombosis in a hepatitis B endemic area. <i>Liver International</i> , 2017, 37, 90-100.	3.9	58
68	Response to Is radiotherapy the best option for treating hepatocellular carcinoma with <scp>PVTT</scp>?. <i>Liver International</i> , 2017, 37, 308-309.	3.9	1
69	Improved oncologic outcome with chemoradiotherapy followed by surgery in unresectable intrahepatic cholangiocarcinoma. <i>Strahlentherapie Und Onkologie</i> , 2017, 193, 620-629.	2.0	17
70	Dose escalation in locally advanced pancreatic cancer patients receiving chemoradiotherapy. <i>Radiotherapy and Oncology</i> , 2017, 123, 438-445.	0.6	48
71	Transarterial Radioembolization Versus Concurrent Chemoradiation Therapy for Locally Advanced Hepatocellular Carcinoma: A Propensity Score Matching Analysis. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017, 99, 396-406.	0.8	15
72	Consensus on Stereotactic Body Radiation Therapy for Small-Sized Hepatocellular Carcinoma at the 7th Asia-Pacific Primary Liver Cancer Expert Meeting. <i>Liver Cancer</i> , 2017, 6, 264-274.	7.7	46

#	ARTICLE	IF	CITATIONS
73	Risk stratification for locally advanced hepatocellular carcinoma using pretreatment alpha-foetoprotein and ¹⁸ F-fluoro-2-deoxyglucose positron emission tomography. <i>Liver International</i> , 2017, 37, 592-599.	3.9	5
74	Prognostic group stratification and nomogram for predicting overall survival in patients who received radiotherapy for abdominal lymph node metastasis from hepatocellular carcinoma: a multi-institutional retrospective study (KROG 15-02). <i>Oncotarget</i> , 2017, 8, 94450-94461.	1.8	15
75	Establishment of a Disease-Specific Graded Prognostic Assessment for Hepatocellular Carcinoma Patients with Spinal Metastasis. <i>Gut and Liver</i> , 2017, 11, 535-542.	2.9	9
76	Radiation improves antitumor effect of immune checkpoint inhibitor in murine hepatocellular carcinoma model. <i>Oncotarget</i> , 2017, 8, 41242-41255.	1.8	89
77	Conditional survival estimate in patients with Barcelona Clinic Liver Cancer stage B/C hepatocellular carcinoma treated with hepatic arterial infusion chemotherapy with/without concurrent radiotherapy. <i>Oncotarget</i> , 2017, 8, 79914-79926.	1.8	7
78	Multi-analyte analysis of cytokines that predict outcomes in patients with hepatocellular carcinoma treated with radiotherapy. <i>World Journal of Gastroenterology</i> , 2017, 23, 2077.	3.3	13
79	Clinical Practice Patterns of Radiotherapy in Patients with Hepatocellular Carcinoma: A Korean Radiation Oncology Group Study (KROG 14-07). <i>Cancer Research and Treatment</i> , 2017, 49, 61-69.	3.0	14
80	Evaluation of Effect of Neoadjuvant Therapy Using Positron Emission Tomography. , 2017, , 45-58.		0
81	Neutrophil-lymphocyte ratio and platelet-lymphocyte ratio as prognostic factors for locally advanced pancreatic cancer patients.. <i>Journal of Clinical Oncology</i> , 2017, 35, 326-326.	1.6	1
82	Can we expect long-term survival in patients with extrahepatic metastasis of hepatocellular carcinoma?. <i>Journal of Clinical Oncology</i> , 2017, 35, 251-251.	1.6	0
83	Establishment of disease-specific graded prognostic assessment for patients with hepatocellular carcinoma and spinal metastasis.. <i>Journal of Clinical Oncology</i> , 2017, 35, 433-433.	1.6	0
84	Efficacy and safety of localized concurrent chemoradiation therapy and sorafenib sequential therapy in advanced hepatocellular carcinoma: A prospective phase II trial.. <i>Journal of Clinical Oncology</i> , 2017, 35, e15678-e15678.	1.6	0
85	Living Donor Liver Transplantation for Advanced Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis after Concurrent Chemoradiation Therapy. <i>Yonsei Medical Journal</i> , 2016, 57, 1276.	2.2	39
86	Re-Irradiation of Hepatocellular Carcinoma: Clinical Applicability of Deformable Image Registration. <i>Yonsei Medical Journal</i> , 2016, 57, 41.	2.2	16
87	Radiotherapy for Adrenal Metastasis from Hepatocellular Carcinoma: A Multi-Institutional Retrospective Study (KROG 13-05). <i>PLoS ONE</i> , 2016, 11, e0152642.	2.5	22
88	Risk Factors Associated with Loco-Regional Failure after Surgical Resection in Patients with Resectable Pancreatic Cancer. <i>PLoS ONE</i> , 2016, 11, e0157196.	2.5	11
89	Application of radiotherapy for hepatocellular carcinoma in current clinical practice guidelines. <i>Radiation Oncology Journal</i> , 2016, 34, 160-167.	1.5	60
90	Radiotherapy for Hepatocellular Carcinoma: New Indications and Directions for Future Study. <i>Journal of the National Cancer Institute</i> , 2016, 108, djw133.	6.3	79

#	ARTICLE	IF	CITATIONS
91	A pilot study of concurrent chemoradiotherapy with gemcitabine and cisplatin in patients with locally advanced biliary tract cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2016, 78, 841-846.	2.3	13
92	Interobserver variability in gross tumor volume delineation for hepatocellular carcinoma. <i>Strahlentherapie Und Onkologie</i> , 2016, 192, 714-721.	2.0	14
93	Optimal Selection of Radiotherapy as Part of a Multimodal Approach for Hepatocellular Carcinoma. <i>Liver Cancer</i> , 2016, 5, 139-151.	7.7	5
94	Consensus for Radiotherapy in Hepatocellular Carcinoma from The 5th Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE 2014): Current Practice and Future Clinical Trials. <i>Liver Cancer</i> , 2016, 5, 162-174.	7.7	53
95	Radiologicalâ€“pathological correlation study of hepatocellular carcinoma undergoing local chemoradiotherapy and surgery. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2016, 31, 1619-1627.	2.8	4
96	Radiation Inhibits Interleukin-12 Production via Inhibition of C-Rel through the Interleukin-6/ Signal Transducer and Activator of Transcription 3 Signaling Pathway in Dendritic Cells. <i>PLoS ONE</i> , 2016, 11, e0146463.	2.5	9
97	The effect of radiotherapy in liver-confined but non-resectable Barcelona Clinic Liver Cancer stage C large hepatocellular carcinoma. <i>Oncotarget</i> , 2016, 7, 62715-62725.	1.8	3
98	Phase I dose-escalation study of helical intensity-modulated radiotherapy-based stereotactic body radiotherapy for hepatocellular carcinoma. <i>Oncotarget</i> , 2016, 7, 40756-40766.	1.8	39
99	High dose and compartmental target volume may improve patient outcome after radiotherapy for pelvic bone metastases from hepatocellular carcinoma. <i>Oncotarget</i> , 2016, 7, 53921-53929.	1.8	11
100	Clinical Benefit of Hepatic Arterial Infusion Concurrent Chemoradiotherapy in Locally Advanced Hepatocellular Carcinoma: A Propensity Score Matching Analysis. <i>Cancer Research and Treatment</i> , 2016, 48, 190-197.	3.0	15
101	Altered Biological Potential and Radioresponse of Murine Tumors in Different Microenvironments. <i>Cancer Research and Treatment</i> , 2016, 48, 727-737.	3.0	5
102	Surgery Alone Versus Surgery Followed by Chemotherapy and Radiotherapy in Resected Extrahepatic Bile Duct Cancer: Treatment Outcome Analysis of 336 Patients. <i>Cancer Research and Treatment</i> , 2016, 48, 583-595.	3.0	38
103	Consensus Development from the 5th Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE 2014). <i>Liver Cancer</i> , 2015, 4, 96-105.	7.7	19
104	Irradiation-induced localization of IL-12-expressing mesenchymal stem cells to enhance the curative effect in murine metastatic hepatoma. <i>International Journal of Cancer</i> , 2015, 137, 721-730.	5.1	31
105	Combination of macrophage inflammatory protein 1 alpha with existing therapies to enhance the antitumor effects on murine hepatoma. <i>Journal of Radiation Research</i> , 2015, 56, 37-45.	1.6	6
106	Predictive Factors of Palliative Radiotherapy Response and Survival in Patients with Spinal Metastases from Hepatocellular Carcinoma. <i>Gut and Liver</i> , 2015, 9, 94-102.	2.9	17
107	Effective Biliary Drainage and Proper Treatment Improve Outcomes of Hepatocellular Carcinoma with Obstructive Jaundice. <i>Gut and Liver</i> , 2014, 8, 526-535.	2.9	16
108	Inhibition of IL-17A Suppresses Enhanced-Tumor Growth in Low Dose Pre-Irradiated Tumor Beds. <i>PLoS ONE</i> , 2014, 9, e106423.	2.5	20

#	ARTICLE	IF	CITATIONS
109	Concurrent Chemoradiotherapy Shows Long-Term Survival after Conversion from Locally Advanced to Resectable Hepatocellular Carcinoma. <i>Yonsei Medical Journal</i> , 2014, 55, 1489.	2.2	18
110	Clinical usefulness of double biomarkers <sc>AFP</sc> and <sc>PIVKA</sc>â€<sc>II</sc> for subdividing prognostic groups in locally advanced hepatocellular carcinoma. <i>Liver International</i> , 2014, 34, 313-321.	3.9	29
111	Dose escalation using helical tomotherapy improves local control in spine metastases from primary hepatic malignancies. <i>Liver International</i> , 2014, 34, 462-468.	3.9	11
112	A Prospective Phase 2 Multicenter Study for the Efficacy of Radiation Therapy Following Incomplete Transarterial Chemoembolization in Unresectable Hepatocellular Carcinoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2014, 90, 1051-1060.	0.8	32
113	Prognostic Values of Vascular Endothelial Growth Factor and Matrix Metalloproteinase-2 in Hepatocellular Carcinoma after Radiotherapy. <i>Digestive Diseases</i> , 2014, 32, 725-732.	1.9	18
114	Multimodality Treatment Involving Radiotherapy for Advanced Liver-Confined Hepatocellular Carcinoma. <i>Oncology</i> , 2014, 87, 90-98.	1.9	16
115	Overall response of both intrahepatic tumor and portal vein tumor thrombosis is a good prognostic factor for hepatocellular carcinoma patients receiving concurrent chemoradiotherapy. <i>Journal of Radiation Research</i> , 2014, 55, 113-120.	1.6	23
116	Neonatal capsaicin treatment in rats affects TRPV1-related noxious heat sensation and circadian body temperature rhythm. <i>Journal of the Neurological Sciences</i> , 2014, 341, 58-63.	0.6	14
117	Therapeutic benefit of radiotherapy in huge (>10cm) unresectable hepatocellular carcinoma. <i>Liver International</i> , 2014, 34, 784-794.	3.9	26
118	<sc>FDG</sc>â€<sc>PET</sc> predicts outcomes of treated bone metastasis following palliative radiotherapy in patients with hepatocellular carcinoma. <i>Liver International</i> , 2014, 34, 1118-1125.	3.9	11
119	Interobserver Variability in Target Definition for Hepatocellular Carcinoma With and Without Portal Vein Thrombus: Radiation Therapy Oncology Group Consensus Guidelines. <i>International Journal of Radiation Oncology Biology Physics</i> , 2014, 89, 804-813.	0.8	33
120	Clinical Usefulness of 18F-Fluorodeoxyglucose-Positron Emission Tomography in Patients With Locally Advanced Pancreatic Cancer Planned to Undergo Concurrent Chemoradiation Therapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2014, 90, 126-133.	0.8	41
121	Improved oncologic outcomes with image-guided intensity-modulated radiation therapy using helical tomotherapy in locally advanced hepatocellular carcinoma. <i>Journal of Cancer Research and Clinical Oncology</i> , 2014, 140, 1595-1605.	2.5	38
122	Surgical Resection After Down-Staging of Locally Advanced Hepatocellular Carcinoma by Localized Concurrent Chemoradiotherapy. <i>Annals of Surgical Oncology</i> , 2014, 21, 3646-3653.	1.5	53
123	Radiotherapeutic Options for Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis. <i>Liver Cancer</i> , 2014, 3, 18-30.	7.7	38
124	Multimodality Management for Barcelona Clinic Liver Cancer Stage C Hepatocellular Carcinoma. <i>Liver Cancer</i> , 2014, 3, 405-416.	7.7	16
125	Multimodality Treatment with Radiotherapy for Huge Hepatocellular Carcinoma. <i>Oncology</i> , 2014, 87, 82-89.	1.9	5
126	Postoperative radiotherapy dose correlates with locoregional control in patients with extra-hepatic bile duct cancer. <i>Radiation Oncology Journal</i> , 2014, 32, 7.	1.5	7

#	ARTICLE	IF	CITATIONS
127	Multicenter Validation Study of a Prognostic Index for Portal Vein Tumor Thrombosis in Hepatocellular Carcinoma. <i>Cancer Research and Treatment</i> , 2014, 46, 348-357.	3.0	12
128	Validation of Group B Borderline Resectable Pancreatic Cancer: Retrospective Analysis. <i>Gut and Liver</i> , 2014, 8, 557-562.	2.9	5
129	Combination treatment of localized concurrent chemoradiation therapy and transarterial chemoembolization in locally advanced hepatocellular carcinoma with intrahepatic metastasis. <i>Cancer Chemotherapy and Pharmacology</i> , 2013, 71, 165-173.	2.3	33
130	Clinical factors related to recurrence after hepatic arterial concurrent chemoradiotherapy for advanced but liver-confined hepatocellular carcinoma. <i>Journal of Radiation Research</i> , 2013, 54, 1069-1077.	1.6	8
131	Usefulness of Positron Emission Tomography With Fluorine-18-Fluorodeoxyglucose in Predicting Treatment Response in Unresectable Hepatocellular Carcinoma Patients Treated With External Beam Radiotherapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2012, 82, 1172-1178.	0.8	27
132	High-dose Helical Tomotherapy With Concurrent Full-dose Chemotherapy for Locally Advanced Pancreatic Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2012, 83, 1448-1454.	0.8	15
133	The significance of ICG α R15 in predicting hepatic toxicity in patients receiving radiotherapy for hepatocellular carcinoma. <i>Liver International</i> , 2012, 32, 1165-1171.	3.9	19
134	Tumor-infiltrating regulatory T cells delineated by upregulation of PD-1 and inhibitory receptors. <i>Cellular Immunology</i> , 2012, 278, 76-83.	3.0	75
135	Combination of Radiotherapy and Adenovirus-Mediated p53 Gene Therapy for MDM2-Overexpressing Hepatocellular Carcinoma. <i>Journal of Radiation Research</i> , 2012, 53, 202-210.	1.6	23
136	Reirradiation to the pelvis for recurrent rectal cancer. <i>Journal of Surgical Oncology</i> , 2012, 105, 637-642.	1.7	59
137	Early on-treatment predictions of clinical outcomes using alpha α -fetoprotein and des γ -carboxy prothrombin responses in patients with advanced hepatocellular carcinoma. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2012, 27, 313-322.	2.8	30
138	The Optimal Selection of Radiotherapy Treatment for Hepatocellular Carcinoma. <i>Gut and Liver</i> , 2012, 6, 139-148.	2.9	23
139	Helical tomotherapy and concurrent gemcitabine-based chemotherapy for locally advanced pancreatic cancer.. <i>Journal of Clinical Oncology</i> , 2012, 30, 318-318.	1.6	0
140	Pattern of failure after hepatic arterial concurrent chemoradiotherapy for locally advanced hepatocellular carcinoma.. <i>Journal of Clinical Oncology</i> , 2012, 30, 299-299.	1.6	0
141	Dose-escalated radiotherapy with helical tomotherapy to spine oligometastasis from intrahepatic malignancies.. <i>Journal of Clinical Oncology</i> , 2012, 30, 325-325.	1.6	0
142	Radiotherapeutic Strategies in the Management of Hepatocellular Carcinoma. <i>Oncology</i> , 2011, 81, 123-133.	1.9	24
143	Asian Consensus Workshop Report: Expert Consensus Guideline for the Management of Intermediate and Advanced Hepatocellular Carcinoma in Asia. <i>Oncology</i> , 2011, 81, 158-164.	1.9	104
144	Multidisciplinary Management of Nonresectable Hepatocellular Carcinoma. <i>Oncology</i> , 2011, 81, 134-140.	1.9	21

#	ARTICLE	IF	CITATIONS
145	Gastroduodenal Complications After Concurrent Chemoradiation Therapy in Patients With Hepatocellular Carcinoma: Endoscopic Findings and Risk Factors. <i>International Journal of Radiation Oncology Biology Physics</i> , 2011, 81, 1343-1351.	0.8	42
146	A Novel Combination Treatment of Armed Oncolytic Adenovirus Expressing IL-12 and GM-CSF with Radiotherapy in Murine Hepatocarcinoma. <i>Journal of Radiation Research</i> , 2011, 52, 646-654.	1.6	34
147	Radiosensitizers in Hepatocellular Carcinoma. <i>Seminars in Radiation Oncology</i> , 2011, 21, 303-311.	2.2	16
148	¹⁸ F-fluorodeoxyglucose uptake on positron emission tomography as a prognostic predictor in locally advanced hepatocellular carcinoma. <i>Cancer</i> , 2011, 117, 4779-4787.	4.1	47
149	Selection of the Optimal Radiotherapy Technique for Locally Advanced Hepatocellular Carcinoma. <i>Japanese Journal of Clinical Oncology</i> , 2011, 41, 882-889.	1.3	21
150	Helical tomotherapy for spine oligometastases from gastrointestinal malignancies. <i>Radiation Oncology Journal</i> , 2011, 29, 219.	1.5	6
151	Is Local Radiotherapy Still Valuable for Patients With Multiple Intrahepatic Hepatocellular Carcinomas?. <i>International Journal of Radiation Oncology Biology Physics</i> , 2010, 77, 1433-1440.	0.8	18
152	Identification of Proteins Indicating Radiation-induced Hepatic Toxicity in Cirrhotic Rats. <i>Journal of Radiation Research</i> , 2010, 51, 643-650.	1.6	15
153	The Efficacy of the Change in Belly Board Aperture Location by the Addition of Bladder Compression Device for Radiotherapy of Rectal Cancer. <i>The Journal of the Korean Society for Therapeutic Radiology and Oncology</i> , 2010, 28, 231.	0.1	2
154	Challenge and Hope in Radiotherapy of Hepatocellular Carcinoma. <i>Yonsei Medical Journal</i> , 2009, 50, 601.	2.2	57
155	The Efficacy of Hepatic Resection after Neoadjuvant Transarterial Chemoembolization (TACE) and Radiation Therapy in Hepatocellular Carcinoma Greater Than 5 cm in Size. <i>Journal of Korean Medical Science</i> , 2009, 24, 242.	2.5	27
156	A multicenter retrospective cohort study of practice patterns and clinical outcome on radiotherapy for hepatocellular carcinoma in Korea. <i>Liver International</i> , 2009, 29, 147-152.	3.9	65
157	Radiotherapeutic Parameters Predictive of Liver Complications Induced by Liver Tumor Radiotherapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2009, 73, 154-158.	0.8	47
158	CA 19-9 as a Predictor for Response and Survival in Advanced Pancreatic Cancer Patients Treated With Chemoradiotherapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2009, 73, 1148-1154.	0.8	45
159	Early Clinical Experience and Outcome of Helical Tomotherapy for Multiple Metastatic Lesions. <i>International Journal of Radiation Oncology Biology Physics</i> , 2009, 73, 1517-1524.	0.8	33
160	Superficial Dosimetry for Helical Tomotherapy. <i>The Journal of the Korean Society for Therapeutic Radiology and Oncology</i> , 2009, 27, 103.	0.1	1
161	Pilot clinical trial of localized concurrent chemoradiation therapy for locally advanced hepatocellular carcinoma with portal vein thrombosis. <i>Cancer</i> , 2008, 113, 995-1003.	4.1	138
162	Enhancement of Tumor Radioresponse by Wortmannin in C3H/HeJ Hepatocarcinoma. <i>Journal of Radiation Research</i> , 2007, 48, 187-195.	1.6	17

#	ARTICLE	IF	CITATIONS
163	Evaluation of the prognostic value of Okuda, Cancer of the Liver Italian Program, and Japan Integrated Staging systems for hepatocellular carcinoma patients undergoing radiotherapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2007, 67, 1037-1042.	0.8	29
164	Radiotherapy for painful bone metastases from hepatocellular carcinoma. <i>Liver International</i> , 2005, 25, 261-265.	3.9	108
165	Local radiotherapy as a complement to incomplete transcatheter arterial chemoembolization in locally advanced hepatocellular carcinoma. <i>Liver International</i> , 2005, 25, 1189-1196.	3.9	111
166	Redox Signaling by Ionizing Radiation in Mouse Liver. <i>Annals of the New York Academy of Sciences</i> , 2004, 1030, 86-94.	3.8	25
167	Enhancement of Tumor Response by Farnesyltransferase Inhibitor in C3H/HeJ Hepatocarcinoma. <i>Annals of the New York Academy of Sciences</i> , 2004, 1030, 95-102.	3.8	8
168	Radiation-Induced Alteration of Pain-Related Signals in an Animal Model with Bone Invasion from Cancer. <i>Annals of the New York Academy of Sciences</i> , 2004, 1030, 179-186.	3.8	14
169	Clinical results and prognostic factors in radiotherapy for unresectable hepatocellular carcinoma: a retrospective study of 158 patients. <i>International Journal of Radiation Oncology Biology Physics</i> , 2003, 55, 329-336.	0.8	160
170	Lethal hepatic injury by combined treatment of radiation plus chemotherapy in rats with thioacetamide-induced liver cirrhosis. <i>International Journal of Radiation Oncology Biology Physics</i> , 2003, 57, 282-288.	0.8	18
171	Clinical results of 3-dimensional conformal radiotherapy combined with transarterial chemoembolization for hepatocellular carcinoma in the cirrhotic patients. <i>Hepatology Research</i> , 2003, 27, 30-35.	3.4	48
172	Treatment of non-resectable hepatocellular carcinoma. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2002, 17, S424-7.	2.8	15
173	Dose-response relationship in local radiotherapy for hepatocellular carcinoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2002, 54, 150-155.	0.8	249
174	Low-Dose Radiation-Induced Adaptive Response in the Murine System. <i>Annals of the New York Academy of Sciences</i> , 2002, 973, 255-257.	3.8	3
175	Enhancement of Radioresponse of Murine Tumors by ERK Inhibitor. <i>Annals of the New York Academy of Sciences</i> , 2002, 973, 371-373.	3.8	5
176	Enhancement of tumor radioresponse by combined chemotherapy in murine hepatocarcinoma. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2001, 16, 883-889.	2.8	29
177	Local radiotherapy for unresectable hepatocellular carcinoma patients who failed with transcatheter arterial chemoembolization. <i>International Journal of Radiation Oncology Biology Physics</i> , 2000, 47, 1331-1335.	0.8	115
178	Early alteration in TGF- β 2 mRNA expression in irradiated rat liver. <i>International Journal of Radiation Oncology Biology Physics</i> , 2000, 46, 639-643.	0.8	41
179	Spontaneous Apoptosis as a Predictor of Radiotherapy in Patients with Stage IIB Squamous Cell Carcinoma of the Uterine Cervix. <i>Acta Oncologica</i> , 1999, 38, 449-454.	1.8	15
180	Combined transcatheter arterial chemoembolization and local radiotherapy of unresectable hepatocellular carcinoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 1999, 43, 393-397.	0.8	153

#	ARTICLE	IF	CITATIONS
181	Combined treatment of radiotherapy and hyperthermia for unresectable hepatocellular carcinoma. Yonsei Medical Journal, 1994, 35, 252.	2.2	14
182	Adaptive response to ionizing radiation induced by low dose of gamma ray in human hepatoma cell lines. Yonsei Medical Journal, 1994, 35, 77.	2.2	12
183	Postoperative radiotherapy for stage IB carcinoma of the uterine cervix. Yonsei Medical Journal, 1990, 31, 367.	2.2	3